Rovalpituzumab

Rovalpituzumab (also known as Rova-T) is an antibody-drug conjugate designed to deliver a potent cytotoxin directly to cancer cells expressing the Delta-like protein 3 (DLL3) antigen, a protein found in more than 80% of small cell lung cancer (SCLC) patient tumors and not present in healthy tissue.

Mechanism of Action

Rovalpituzumab works by targeting the DLL3 protein on the surface of cancer cells and delivering a cytotoxic agent directly to the cells. The drug is composed of a monoclonal antibody linked to a cytotoxic agent. The antibody portion of the drug binds to the DLL3 protein on the cancer cell, and the cytotoxic agent is then released into the cell, causing cell death.

Clinical Trials

Rovalpituzumab has been studied in several clinical trials for the treatment of SCLC. In a phase I/II clinical trial, Rovalpituzumab showed promising results in patients with SCLC who had progressed after initial therapy. However, in a subsequent phase III trial, the drug did not meet its primary endpoint of improved overall survival.

Side Effects

Common side effects of Rovalpituzumab include fatigue, nausea, decreased appetite, and vomiting. Serious side effects can include severe allergic reactions, infusion-related reactions, and severe skin reactions.

Future Research

Despite the disappointing results of the phase III trial, research into Rovalpituzumab and other drugs targeting DLL3 continues. Scientists are exploring different ways to target this protein, including using different types of drugs or combining Rovalpituzumab with other treatments.